Purdue Pharma Lp Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PURDUE PHARMA LP, and what generic alternatives to PURDUE PHARMA LP drugs are available?
PURDUE PHARMA LP has ten approved drugs.
There are sixty-five US patents protecting PURDUE PHARMA LP drugs.
There are four hundred and eighty-two patent family members on PURDUE PHARMA LP drugs in fifty-one countries and one supplementary protection certificate in one country.
Summary for Purdue Pharma Lp
| International Patents: | 482 |
| US Patents: | 65 |
| Tradenames: | 10 |
| Ingredients: | 9 |
| NDAs: | 10 |
Drugs and US Patents for Purdue Pharma Lp
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Purdue Pharma Lp | HYSINGLA ER | hydrocodone bitartrate | TABLET, EXTENDED RELEASE;ORAL | 206627-003 | Nov 20, 2014 | AB | RX | Yes | No | 11,304,908 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Purdue Pharma Lp | ZURNAI (AUTOINJECTOR) | nalmefene hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 218590-001 | Aug 7, 2024 | RX | Yes | Yes | 11,185,642 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Purdue Pharma Lp | HYSINGLA ER | hydrocodone bitartrate | TABLET, EXTENDED RELEASE;ORAL | 206627-006 | Nov 20, 2014 | AB | RX | Yes | No | 8,808,740 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Purdue Pharma Lp
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Purdue Pharma Lp | TARGINIQ | naloxone hydrochloride; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205777-003 | Jul 23, 2014 | 8,673,355 | ⤷ Sign Up |
| Purdue Pharma Lp | BUTRANS | buprenorphine | FILM, EXTENDED RELEASE;TRANSDERMAL | 021306-002 | Jun 30, 2010 | 9,642,850 | ⤷ Sign Up |
| Purdue Pharma Lp | TARGINIQ | naloxone hydrochloride; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205777-002 | Jul 23, 2014 | 8,846,091 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PURDUE PHARMA LP drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 20 mg, 60 mg, and 120 mg | ➤ Subscribe | 2015-04-15 |
| ➤ Subscribe | Extended-release Tablets | 15 mg | ➤ Subscribe | 2007-02-15 |
| ➤ Subscribe | Transdermal System | 15 mcg/hr | ➤ Subscribe | 2013-12-16 |
| ➤ Subscribe | Extended-release Tablets | 30 mg, 40 mg, 80 mg, and 100 mg | ➤ Subscribe | 2015-05-08 |
| ➤ Subscribe | Extended-release Tablets | 30 mg and 60 mg | ➤ Subscribe | 2007-01-03 |
| ➤ Subscribe | Transdermal System | 5 mcg/hr, 10 mcg/hr, and 20 mcg/hr | ➤ Subscribe | 2013-06-06 |
International Patents for Purdue Pharma Lp Drugs
Supplementary Protection Certificates for Purdue Pharma Lp Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1685839 | 92292 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
